Ligand Pharmaceuticals (FRA:LGDN) 3-Year Revenue Growth Rate : -8.70% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Ligand Pharmaceuticals 3-Year Revenue Growth Rate?

Ligand Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was €1.46.

During the past 12 months, Ligand Pharmaceuticals's average Revenue per Share Growth Rate was -36.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -8.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Ligand Pharmaceuticals was 91.00% per year. The lowest was -65.00% per year. And the median was 10.30% per year.

Competitive Comparison of Ligand Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Ligand Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ligand Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Ligand Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Ligand Pharmaceuticals (FRA:LGDN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Ligand Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ligand Pharmaceuticals (FRA:LGDN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (FRA:LGDN) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

LGND:USA

Address

3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121

Website

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals (FRA:LGDN) Headlines

No Headlines